NCT00526136

Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 735 (actual)
• Sponsor: Advanz Pharma · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety, tolerability and efficacy of 3 doses of vernakalant (oral) (150 mg, 300 mg and 500 mg b.i.d.) administered for up to 90 days in subjects with sustained symptomatic atrial fibrillation (AF duration \> 72 hours and \< 6 months).

Conditions

• Atrial Fibrillation

Interventions

Type	Name	Description
DRUG	Placebo
DRUG	Vernakalant (oral)	Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)

Timeline

• Start date: 2007-03-01
• Completion: 2008-07-01
• First posted: 2007-09-10
• Last updated: 2008-12-18

Locations

152 sites across 24 countries: Australia, Belgium, Bulgaria, Croatia, Czechia, Denmark, Estonia, Germany, Hungary, Lithuania, Netherlands, New Zealand, Poland, Portugal, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Ukraine